Latest Financial Results
Q1 2024
Quarter Ended Mar 31, 2024
$111.0M
Net sales were up 2% to $111.0 million compared to $108.6 million (up 4% in constant currency).
$2.3M
GAAP net income attributable to common shareholders up significantly to $2.3 million, or $0.12 per diluted common share, compared to $0.9 million, or $0.04 per diluted common share.
$9.2M
Adjusted EBITDA up slightly to $9.2 million compared to $9.1 million.
Source: Q1 2024 Earnings Release
For complete information regarding our financials, see our periodic filings.
Stock Information
Environmental, Social and Governance
An Investment You Can Feel Good About
Nature’s Sunshine provides over 600 products across the globe, investing in the people and world around us. No one obsesses over results like we do, and we have prioritized our environmental, social and governance efforts to become a company our shareholders can depend on. Join us as we take health to new heights.
View ESGNature’s Sunshine Products at a Glance
4
Geographic segments: Asia, Europe, North America and Latin America/Other
6
Product lines: General Health, Immune, Cardiovascular, Digestive, Personal Care and Weight Management
800
Employees, as of December 31, 2022
As of Dec. 31, 2022 • 10-K 2022
Revenue At-A-Glance for 2022
Revenue by Geographic Segment
In thousands
Revenue by Product Category
As of Dec. 31, 2022 • 10-K 2022
For complete information regarding our financials, see our periodic filings.
Healthy Products Are Born from Healthy Companies
IR Contacts
Company
Nature’s Sunshine Products, Inc.
2901 W Blue Grass Blvd.
Lehi, UT 84043
Investor Relations
Gateway Group
Cody Slach
T: 949-574-3860
NATR@gateway-grp.com
Transfer Agent
American Stock Transfer & Trust
40 Wall Street
New York, NY 10005
T: 800-937-5449
help@astfinancial.com